Acrux receives $0.55m advance on FY26 R&D Tax Incentive
Filed with ASX · · 1 page · English
Summary by 6ix AI
This funding will support the development of products and working capital management following FDA confirmation of Acrux’s Hormone Replacement Therapy regulatory pathway. The advance represents a significant portion of the estimated R&D Tax Incentive for a defined four-month period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Acrux
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream
- AGM Presentation and Address
- Acrux receives $0.4m advance on FY26 R&D Tax Incentive
Later from Acrux
- Acrux strategy focuses on Female Testosterone for low libido
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
- Acrux raises $1.6 million via Share Placement
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux licenses Lenzetto for Australian market for AUD5.4m
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux